These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 7622824)

  • 1. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
    den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA; Westenberg HG
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
    Zohar J; Westenberg HG
    Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin-influencing drugs in the treatment of panic disorder.
    Westenberg HG; den Boer JA
    Psychopathology; 1989; 22 Suppl 1():68-77. PubMed ID: 2498967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression].
    Semba J
    Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):79-84. PubMed ID: 10976459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
    Peter H; Tabrizian S; Hand I
    Int J Psychiatry Med; 2000; 30(1):27-39. PubMed ID: 10900559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective serotonin reuptake inhibitor(SSRI)].
    Motohashi N
    Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors].
    Yamauchi M; Hiraoka S; Imanishi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):193-8. PubMed ID: 17240844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan].
    Hachisu M; Ichimaru Y
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):271-9. PubMed ID: 10872178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients.
    Peter H; Hand I; Hohagen F; Koenig A; Mindermann O; Oeder F; Wittich M
    Can J Psychiatry; 2002 Aug; 47(6):557-61. PubMed ID: 12211884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
    den Boer JA
    J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
    Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
    Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin-reuptake inhibitors: an update.
    Masand PS; Gupta S
    Harv Rev Psychiatry; 1999; 7(2):69-84. PubMed ID: 10471245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.